Wells Fargo Maintains Overweight on WAVE Life Sciences, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 86.5%

Neg 86.5% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from $27 to $13.